These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28196209)

  • 21. Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer.
    Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Imai A; Okamoto A; Hamaoka A; Soushi M; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Goto M; Yamada K; Taguchi T
    Breast Cancer; 2017 Jan; 24(1):92-97. PubMed ID: 26874836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
    Xu B; Hu X; Zheng H; Wang X; Zhang Q; Cui S; Liu D; Liao N; Luo R; Sun Q; Yu S
    Oncotarget; 2016 Aug; 7(31):50643-50655. PubMed ID: 27276706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.
    Wu YY; Huang TC; Tsai TN; Chen JH; Dai MS; Chang PY; Ho CL; Ye RH; Chung TR; Chen YC; Chao TY
    PLoS One; 2016; 11(3):e0151112. PubMed ID: 26953588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trial Validates Biosimilar for Trastuzumab.
    Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience.
    Dao BD; Ho H; Quintal LN
    J Oncol Pharm Pract; 2016 Apr; 22(2):261-4. PubMed ID: 25802300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
    Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
    J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How can biosimilars change the trajectory of breast cancer therapy?
    Trapani D; Curigliano G
    Expert Rev Anticancer Ther; 2020 May; 20(5):325-328. PubMed ID: 32298188
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
    Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
    Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer.
    Ferretti G; Papaldo P; Fabi A; Carlini P; Felici A; Cognetti F
    Oncologist; 2006; 11(7):853-4. PubMed ID: 16880245
    [No Abstract]   [Full Text] [Related]  

  • 34. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 testing in patients with breast cancer.
    Dixon JM; Wilson V; Verrill M; Symmans WF
    BMJ; 2012 Jun; 344():e3958. PubMed ID: 22689887
    [No Abstract]   [Full Text] [Related]  

  • 38. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.
    Kurozumi S; Inoue K; Takei H; Matsumoto H; Kurosumi M; Horiguchi J; Takeyoshi I; Oyama T
    BMC Cancer; 2015 Sep; 15():622. PubMed ID: 26345461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer].
    Guo J; Xu B; Ma F; Fan Y; Yuan P; Wang J; Cai R; Li Q; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):372-6. PubMed ID: 25030594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.